Legal Representation
Attorney
Norm J. Rich
USPTO Deadlines
Application History
23 events| Date | Code | Type | Description |
|---|---|---|---|
| Feb 27, 2025 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Aug 29, 2024 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Aug 29, 2024 | GNSL | F | LETTER OF SUSPENSION E-MAILED |
| Aug 29, 2024 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Jun 27, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Jun 27, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Jun 27, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Jun 27, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Jun 11, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Jun 11, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Jun 11, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Jun 11, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Apr 23, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Apr 23, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Apr 23, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Feb 28, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Jan 29, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jan 29, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 29, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jan 23, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Jun 9, 2023 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Jun 8, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| May 13, 2023 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 001
Therapeutic proteins for use in the manufacture of pharmaceutical preparations
Class 005
Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer
Class 042
Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, and fusion proteins, used to treat cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and products development for others in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals for use in the treatment of cancer and cancer-related disorders; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development for others of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical products development for others in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and products development for others in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology
Class 044
Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment
Additional Information
Design Mark
The mark consists of the word "MURAL" in stylized, capitalized font positioned above the word "ONCOLOGY" in stylized, capitalized font within the image of an incomplete circle that surrounds the wording and has a small break or opening to the left of the aforementioned text.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
001
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
ONCOLOGY